Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer

By Cullen Kevin   Yang Zejia   Schumaker Lisa   Guo Zhongmin  

Journal of Bioenergetics and Biomembranes, Vol. 39, Iss. 1, 2007-02 ,pp. : 43-50

Springer Publishing Company

Access to resources Recommend Favorite

Zalutumumab in head and neck cancer

By Schick Ulrike   Gujral Dorothy M   Richards Tom M   Harrington Kevin J   Nutting Christopher M  

Expert Opinion on Biological Therapy, Vol. 12, Iss. 1, 2012-01 ,pp. : 119-125

Informa Healthcare

Access to resources Recommend Favorite

Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer

By Kyula Joan N   Roulstone Victoria   Karapanagiotou Eleni M   Melcher Alan A   Harrington Kevin J  

Expert Opinion on Biological Therapy, Vol. 12, Iss. 12, 2012-12 ,pp. : 1669-1678

Informa Healthcare

Access to resources Recommend Favorite

Immune alterations and immunotherapy prospects in head and neck cancer

By Varilla Vincent  

Expert Opinion on Biological Therapy, Vol. 13, Iss. 9, 2013-09 ,pp. : 1241-1256

Informa Healthcare

Access to resources Recommend Favorite

Selenium and immunocompetence in patients with head and neck cancer

By Kiremidjian-Schumacher L.   Roy M.   Glickman R.   Schneider K.   Rothstein S.   Cooper J.   Hochster H.   Kim M.   Newman R.  

Biological Trace Element Research, Vol. 73, Iss. 2, 2000-02 ,pp. : 97-111

Humana Press, Inc

Access to resources Recommend Favorite